Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 138,752,791
- Total 13F shares
- 87,478,919
- Share change
- +36,024,295
- Total reported value
- $216,988,373
- Put/Call ratio
- 42%
- Price per share
- $2.48
- Number of holders
- 97
- Value change
- +$93,728,957
- Number of buys
- 54
- Number of sells
- 36
Report period
Q4 2024
Institutions
97
Top holders
10
ACRS full security history
Newer quarter: Q1 2025
Previous quarter: Q3 2024
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BML Capital Management, LLC |
13F
|
Company |
10%
|
14,250,000
|
$16,387,500 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
4,685,498
|
$5,388,323 | — | 30 Sep 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.4%
|
3,371,849
|
$3,877,627 | — | 30 Sep 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.2%
|
3,005,598
|
$3,456,438 | — | 30 Sep 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
2%
|
2,753,495
|
$3,166,519 | — | 30 Sep 2024 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
1.8%
|
2,458,873
|
$2,827,704 | — | 30 Sep 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.5%
|
2,078,287
|
$2,388,000 | — | 30 Sep 2024 | |
| Trium Capital LLP |
13F
|
Company |
1.4%
|
1,912,990
|
$2,200,000 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
1.2%
|
1,711,797
|
$1,968,568 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.99%
|
1,370,700
|
$1,576,305 | — | 30 Sep 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.94%
|
1,301,500
|
$1,496,725 | — | 30 Sep 2024 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.75%
|
1,043,152
|
$1,199,625 | — | 30 Sep 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.67%
|
923,313
|
$1,061,810 | — | 30 Sep 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.66%
|
915,509
|
$1,052,835 | — | 30 Sep 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.65%
|
907,916
|
$1,044,103 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.61%
|
846,446
|
$973,577 | — | 30 Sep 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.5%
|
696,171
|
$800,597 | — | 30 Sep 2024 | |
| Acuitas Investments, LLC |
13F
|
Company |
0.42%
|
578,139
|
$664,860 | — | 30 Sep 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
0.41%
|
569,832
|
$655,307 | — | 30 Sep 2024 | |
| FMR LLC |
13F
|
Company |
0.39%
|
545,972
|
$627,867 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.35%
|
480,773
|
$552,889 | — | 30 Sep 2024 | |
| Aisling Capital Management LP |
13F
|
Company |
0.31%
|
434,455
|
$499,623 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.26%
|
364,567
|
$419,252 | — | 30 Sep 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.24%
|
332,406
|
$382,267 | — | 30 Sep 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.22%
|
305,814
|
$352,000 | — | 30 Sep 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.22%
|
301,556
|
$346,789 | — | 30 Sep 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.21%
|
292,845
|
$336,772 | — | 30 Sep 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.19%
|
264,377
|
$304,034 | — | 30 Sep 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.18%
|
255,032
|
$293,000 | — | 30 Sep 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.14%
|
199,119
|
$228,987 | — | 30 Sep 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.14%
|
188,721
|
$217,029 | — | 30 Sep 2024 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.13%
|
185,777
|
$213,644 | — | 30 Sep 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.1%
|
140,580
|
$161,667 | — | 30 Sep 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.1%
|
139,400
|
$161,000 | — | 30 Sep 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.09%
|
127,225
|
$146,309 | — | 30 Sep 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.06%
|
90,000
|
$103,500 | — | 30 Sep 2024 | |
| Marquette Asset Management, LLC |
13F
|
Company |
0.06%
|
83,979
|
$96,576 | — | 30 Sep 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.06%
|
82,727
|
$95,136 | — | 30 Sep 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.06%
|
76,810
|
$88,332 | — | 30 Sep 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.04%
|
62,408
|
$71,769 | — | 30 Sep 2024 | |
| BBR PARTNERS, LLC |
13F
|
Company |
0.04%
|
60,000
|
$69,000 | — | 30 Sep 2024 | |
| Point72 Asia (Singapore) Pte. Ltd. |
13F
|
Company |
0.04%
|
52,052
|
$59,860 | — | 30 Sep 2024 | |
| Mariner, LLC |
13F
|
Company |
0.03%
|
48,101
|
$55,316 | — | 30 Sep 2024 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.03%
|
41,873
|
$48,000 | — | 30 Sep 2024 | |
| Engineers Gate Manager LP |
13F
|
Company |
0.03%
|
38,794
|
$44,613 | — | 30 Sep 2024 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.02%
|
33,183
|
$38,160 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
31,852
|
$36,631 | — | 30 Sep 2024 | |
| Shay Capital LLC |
13F
|
Company |
0.02%
|
27,000
|
$31,050 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
21,909
|
$25,195 | — | 30 Sep 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
20,393
|
$23,452 | — | 30 Sep 2024 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q4 2024
As of 31 Dec 2024,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
97 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,478,919 shares.
The largest 10 holders included
BML Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vivo Capital, LLC, Rock Springs Capital Management LP, RA CAPITAL MANAGEMENT, L.P., VANGUARD GROUP INC, D. E. Shaw & Co., Inc., JANUS HENDERSON GROUP PLC, MARSHALL WACE, LLP, and Samsara BioCapital, LLC.
This page lists
98
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
76
Q4 2024 holders
97
Holder diff
21
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.